Key result
Hypertril improves myocardial morpho-functional parameters over metoprolol in experimental chronic heart failure.
Why the study?
Hypertril is a promising drug with beta-blocker and NO-mimetic properties for cardiovascular diseases, but its cardioprotective effects in chronic heart failure require investigation.
Does Hypertril improve morpho-functional parameters of the myocardium in rats with doxorubicin-induced chronic heart failure?
Does Hypertril improve morpho-functional parameters of the myocardium in rats with doxorubicin-induced chronic heart failure?
p-value: p=< 0.05
The novel 1,2,4-triazole derivative Hypertril showed superior cardioprotective effects compared to metoprolol in a rat model of doxorubicin-induced heart failure.
Bromide 1 - (β-phenylethyl)-4-amino-1,2,4-triazolium (Hypertril) has the properties of a beta-blocker and of NO-mimetic, is assigned to the IV class of toxicity. All these effects make Hypertril a promising drug for the treatment of cardiovascular diseases. The aim of this paper was to study the cardioprotective action of Hypertril in terms of the effect on the morpho-functional parameters of the myocardium in rats with experimental chronic heart failure (CHF). CHF was modeled on 80 white outbred rats weighing 190–220g by administering doxorubicin at a cumulative dose of 15 mg/kg. Hypertril and the reference drug metoprolol succinate were administered within 30 days after CHF modeling, intragastrically at doses of 3.5 mg/kg and 15 mg/kg. Morphometric analysis of the cellular structure of the myocardium was carried out on an Axioskop microscope (Zeiss, Germany), in an automatic mode using a macro program developed in a specialized programming environment VIDAS-2.5 (Kontron Elektronik, Germany). The administration of Hypertril to animals with CHF led to an increase in the density of nuclei of cardiomyocytes, the area of myocardiocyte nuclei, an increase in the nuclear cytoplasmic ratio and an increase in the concentration of RNA in the nuclei and cytoplasm of cardiomyocytes compared with the group of untreated animals, which indicated the presence of a pronounced cardioprotective effect in the drug candidate. In terms of such indicators as the density of surviving cardiomyocytes and the content of RNA in them, the nuclear-cytoplasmic ratio of Hypertril is significantly (p < 0.05) superior to metoprolol.
No takes yet. Share an insight, caveat, or question.
Bak et al. (2021) studied experimental chronic heart failure (CHF) (n=80). Bromide 1 - (β-phenylethyl)-4-amino-1,2,4-triazolium (Hypertril) vs. metoprolol succinate (15 mg/kg) and untreated animals was evaluated on morpho-functional parameters of the myocardium (density of surviving cardiomyocytes, RNA content, nuclear-cytoplasmic ratio) (p=< 0.05). In rats with experimental chronic heart failure, Hypertril significantly improved surviving cardiomyocyte density, RNA content, and nuclear-cytoplasmic ratio compared to metoprolol (p < 0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: